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Abstract
Background: Macrolide resistance in Helicobacter pylori is the major risk factor for treatment failure when using a
proton pump inhibitor-clarithromycin containing therapy. Macrolide resistance is due to a few mutations on the
23S ribomosal subunit encoded by the 23S rRNA gene. The present study aimed at investigating the performance
of the dual priming oligonucleotide (DPO)-PCR kit named Seeplex® ClaR-H. pylori ACE detection designed to detect
H. pylori and two types of point mutations causing clarithromycin resistance in H. pylori.
Methods: The performance of Seeplex® ClaR-H. pylori ACE detection was evaluated on 127 gastric biopsies in
comparison to conventional bacterial culture followed by the determination of susceptibility to clarithromycin by
E-test, as well as by an in-house real-time PCR using a fluorescence resonance energy transfer (FRET) technology.
Results: Considering culture as the reference test, the sensitivity of DPO-PCR and real-time FRET-PCR was 97.7%
and 100% while specificity was 83.1% and 80.7%, respectively. However, both PCR were concordant in detecting 14
H. pylori positive cases which were negative by culture. Globally, E-test and DPO-PCR were concordant with regard
to clarithromycin susceptibility in 95.3% of the cases (41/43), while real-time FRET-PCR and DPO-PCR were
concordant in 95% (57/60).
Conclusion: The DPO-PCR is an interesting tool to detect H. pylori on gastric biopsies and to study its susceptibility
to clarithromycin in laboratories that cannot perform real-time PCR assays.
Background
Macrolide resistance in Helicobacter pylori is the major
risk factor for treatment failure when using a proton
pump inhibitor (PPI)-clarithromycin containing therapy
[1]. Macrolide resistance is due to a few mutations on the
23S ribomosal subunit encoded by the 23S rRNA gene
[2,3]. These mutations (A2142C, A2142G, A2143G), are
easy to detect by numerous molecular methods directly
on gastric biopsy specimens and even on stool samples
[4-7].
A new PCR format named DPO-PCR for “Dual Prim-
ing Oligonucleotide” was recently developed [8]. DPO-
PCR is a multiplex PCR assay that increases specificity
and sensitivity of detection compared to conventional
PCR, by blocking non-specific binding sites therefore
eliminating imperfect primer annealing. This new tech-
nology can be used for many applications in the field of
in vitro diagnostics: simultaneous detection of multiple
pathogens and of polymorphisms (SNPs), as well as
simultaneous genotyping of multiple pathogen subtypes.
DPO-PCR is based on a multiplex PCR using a DPO
patented technology [8]. The structure of the DPO pri-
mers is fundamentally different from that of conventional
primers. Indeed, the primer is divided into two parts by a
5 polydeoxyinosine linker which allows a more specific
hybridization at temperatures between 55 and 65°C. This
linker forms a “bubble-like structure” which itself is not
involved in priming, rather it delineates the boundary
between two parts. It therefore generates two recognition
reactions of the primer on the target sequence. Accord-
ing to the manufacturer (see http://www.seegene.com/
en/research/core_020.php), the 5’ end (approximately 20
bases) binds preferentially to the matrix and initiates
stable annealing acting as a “stabilizer”. The 3’ end is
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shorter (approximately 10 bases) and binds afterwards to
the target site but only if the first step has taken place
without a mismatch. The 3’ end determines a target-spe-
cific extension and acts as a “determiner”. Therefore,
although the longer 5’-segment binds to a non-target site,
the shorter segment resists non-specific extension. The
short 3’-portion alone fails to make a priming at an
annealing temperature. The latter also binds preferen-
tially to the target and avoids non-specific binding. This
PCR can be performed in any conventional thermocycler.
The performance of this PCR format for the detection
of H. pylori 23S rDNA mutations, involved in macrolide
resistance was previously evaluated in a study published
in 2007 by Woo et al., [9] with a 94.1% concordance
between the DPO-based multiplex PCR and culture fol-
lowed by a phenotypic susceptibility test.
In an article by Cho AR and Lee MK in Korean lan-
guage, they also compared this method to culture and his-
tology, and concluded that it could be used for the
diagnosis of H. pylori infection and the determination of
clarithromycin resistance [10]. However, they used a disk
diffusion method which is not a generally accepted techni-
que for testing H. pylori antimicrobial susceptibility. The
present study is a retrospective study performed by the
National Reference Centre for Helicobacters in France
which aimed at investigating the performance of the See-
plex® ClaR-H. pylori ACE detection kit (Seegene, Seoul,
Korea) in comparison to standard phenotypic tests as well
as the real-time fluorescence resonance energy transfer
(FRET)-PCR developed and routinely used in our labora-
tory [7].
Methods
Materials
The Seeplex® ClaR-H. pylori ACE detection kit was evalu-
ated retrospectively on DNAs extracted from 127 gastric
biopsies received at the French National Reference Centre
for Helicobacters (Bordeaux, France) during the year 2009.
There was no preselection according to the gastric site.
Consecutive biopsies were included until about half of the
number of biopsies positive for H. pylori was attained.
Methods
The performance of the kit was compared to conventional
bacterial culture followed by the determination of suscept-
ibility to clarithromycin by E-test, and an in-house real-
time PCR detection using the FRET technology [7].
Culture
H. pylori strains were obtained from the corresponding
gastric biopsies, after culture on Wilkins-Chalgren agar
plates (Oxoid, Dardilly, France) supplemented with human
blood (10% v/v) and antibiotics (10 μg/ml of vancomycin,
10 μg/ml of cefsulodin, 5 μg/ml of trimethoprim, and
10 μg/ml of amphotericin B) under microaerobic condi-
tions, as already described [11,12]. Forty-four culture posi-
tive cases were finally included.
Phenotypic susceptibility testing
Susceptibility to clarithromycin was assessed using the
E-test method (bioMérieux, Marcy l’Etoile, France) per-
formed as previously described [6] and using the
EUCAST breakpoints: S ≤ 0.25 μg/ml; R > 0.5 μg/ml
(http://www.eucast.org/clinical_breakpoints/).
DNA extraction from gastric biopsies
Genomic DNA from gastric biopsies was extracted by
using the MagnaPure LC DNA Isolation Kit I and the
MagnaPure LC Isolation Station (Roche Applied Science,
Penzberg, Germany). DNAs were stored at -20°C until
required for analysis.
Real-time FRET-PCR
The real-time FRET-PCR is designed to detect clarithro-
mycin susceptible H. pylori (wild type) and the muta-
tions responsible for clarithromycin resistance: A4142G
and A2143G, without distinguishing between them, as
well as A2142C. This test was performed as previously
described [7].
DPO-PCR
DPO-PCR was performed using the Seeplex® ClaR-H.
pylori ACE detection kit according to the manufacturer’s
recommendations (Seegene distributed by Eurobio
Laboratoires, Courtaboeuf, France) and analyzed using a
semi-automated system called Screen tape® allowing an
ultra rapid migration and analysis of the PCR products in
small polyacrylamide gels. 8-methoxysporalen was added
during the mix preparation to intercalate between dou-
ble-stranded nucleic acids generated during amplifica-
tion, thereby limiting carry-over contamination after UV
irradiation and before PCR product analysis. The See-
plex® ClaR-H. pylori ACE detection kit includes 3 primer
pairs with a DPO structure which allows amplification of
the H. pylori 23S rDNA (621 bp amplicon) and detection
of A2142G and A2143G mutations (194 bp and 475 bp,
respectively). The kit also includes a primer pair for
internal control.
DPO-PCR is a multiplex PCR that can be performed
in any standard thermocycler.
Histology
Briefly, histological preparations were stained with
hematoxylin and eosin and Giemsa stains and the pre-
sence of H. pylori was evaluated according to the Sydney
system. Histological results were used only in case of
discrepant results obtained between DPO-PCR and
FRET-PCR.
Lehours et al. BMC Gastroenterology 2011, 11:112
http://www.biomedcentral.com/1471-230X/11/112
Page 2 of 5
Evaluation of Sensitivity and Specificity
The proportion of positives by DPO-PCR among the
true positives defined the sensitivity and the proportion
of negatives by DPO-PCR among the true negatives
defined the specificity.
Results
Concerning the 127 biopsies included in the study, cul-
ture was positive for H. pylori in 44 cases (34.6%), the
real-time FRET-PCR in 60 cases (47.2%), and the DPO-
PCR in 57 cases (44.9%). H. pylori status obtained from
histological diagnosis was available for only 89 patients.
For the 44 biopsies positive by culture, the real-time
FRET-PCR and DPO-PCR were also positive, except in
one case where DPO-PCR was solely negative. For 67
biopsies, culture, FRET-PCR and DPO-PCR were all
negative. Out of 16 biopsies negative by culture, FRET-
PCR, DPO-PCR and histology were all positive for 14.
For the remaining 2 biopsies, real-time FRET-PCR was
solely positive (Tables 1 and 2) and histology confirmed
the presence of H. pylori.
Using culture as the reference test, the sensitivity of
DPO-PCR and real-time FRET PCR was 97.7% and
100%, respectively, and the specificity was 83.1% and
80.7%, respectively.
The concordance between real-time FRET-PCR and
DPO-PCR in our study was 95% (57/60) (Table 2). Con-
sidering the 44 H. pylori strains isolated by culture, clar-
ithromycin susceptibility results were available for 43
(one strain being lost after subculture). Table 2 sum-
marizes the results obtained by the three methods used
for determining macrolide susceptibility. For the 17 clar-
ithromycin susceptible isolates, 15 corresponding biop-
sies contained a wild type isolate in both PCR formats.
One biopsy was categorized as wild type by FRET-PCR
and as an A2143G mutant by DPO-PCR. The remaining
biopsy was considered to be a mixture of wild type and
A2142G/A2143G mutant by FRET-PCR whereas DPO-
PCR detected an A2143G mutation.
For the 26 macrolide resistant isolates, a 23S rDNA
mutation was detected in 25 biopsies by both PCR for-
mats. One biopsy was considered as a wild type by real-
time FRET-PCR but was negative by DPO-PCR (histol-
ogy was also negative).
Globally, E-test and DPO-PCR were concordant in
95.3% of these cases (41/43).
Discussion
We found a good correlation for the detection of
H. pylori and the detection of clarithromycin susceptibil-
ity between the DPO-PCR and the real-time FRET-PCR
routinely used in our Reference Centre. Overall, the per-
formance is very good for a non-real-time PCR format.
Compared to other PCR formats developed to detect
mutations involved in macrolide resistance for H. pylori,
DPO-PCR requires no investment in additional technical
or expensive detection devices. One disadvantage is that
users must run the detection of PCR fragments them-
selves on a 2% agarose gel before analyzing the PCR
bands obtained, compared to real-time PCR formats
available to date where PCR amplification is monitored
automatically. DPO-PCR is therefore more time-con-
suming. However, in our study the semi-automated sys-
tem called ScreenTape® was used. ScreenTape®
simplifies the analysis of the results of this multiplex
PCR assay.
The cost of the test is highly dependent on the activity
and equipment of the laboratory in which the test is
performed; however, it is significantly higher than the
cost of the in-house method tested in parallel in the
present study.
DPO-PCR detected more H. pylori positive biopsies
than culture alone, with an excellent correlation with
the FRET-PCR. Woo et al., identified 49 H. pylori posi-
tive samples among 165 culture-negative specimens
using DPO-PCR [9]. This result leads us to believe that
there is no specificity problem regarding DPO-PCR,
rather a problem of sensitivity regarding culture.
The excellent correlation between DPO-PCR and E-test
susceptibility is in line with the previous study published
by Woo et al., where they found a 94.1% concordance
between both methods [9]. In the work of Woo et al., two
strains categorized as susceptible by E-test appeared resis-
tant by DPO-PCR. Cho et al., also described that the
results of PCR and E-test on 3 of the 8 mutation-positive
biopsies were discrepant [10]. In the present study, DPO-
PCR detected resistances missed by E-test also in two
cases (Table 2). This could be explained by the detection
Table 1 Global results obtained for different diagnosis tests for the detection of Helicobacter pylori in human gastric
biopsies
Culture (n = 44) FRET-PCR (n = 60) DPO-PCR (n = 57) Total (n = 127)
(+) (+) (+) 43
(+) (+) (-) 1
(-) (-) (-) 67
(-) (+) (+) 14
(-) (+) (-) 2
The numbers indicated in parentheses represent the total number of positive samples for each test.
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limit of the Seeplex® ClaR-H. pylori ACE detection kit
which is 100 copies/reaction (100 copies/3 μl DNA).
According to Woo HY et al., DPO-PCR can detect
mutants present among wild-type strains at a level as low
as 2% and more than 100 copies/20 μl [9]. For such a low
proportion, the E-test method missed a resistant strain.
The Seeplex® ClaR-H. pylori ACE detection kit does
not allow detection of the A2142C mutation. However,
this mutation is less common (usually <5% of resistant
isolates) [7,5].
As indicated in the Materials and Methods, the See-
plex® ClaR-H. pylori ACE detection kit includes 3 pri-
mer pairs with a DPO structure which allows
amplification of the H. pylori 23S rDNA (621 bp ampli-
con) and detection of the A2142G and A2143G muta-
tions (194 bp and 475 bp, respectively). The first primer
pair is designed to hybridize regardless of the presence
of any mutation inside the PCR fragments. In the case
of the A2142G mutation, its specific primer hybridizes
and generates a 194 bp PCR product with the reverse
H. pylori 23S rDNA primer. In the case of the A2143G
mutation, its specific primer hybridizes and forms a 475
bp PCR product with the forward H. pylori 23S rDNA
primer. Therefore, it is not possible to distinguish
between 1) gastric biopsies containing a mixture of a
wild-type strain and a mutated strain and 2) biopsies
containing only a mutated strain (the 621 bp band cor-
responding to amplification of H. pylori 23S rDNA is
almost always present). It has no practical consequences
because the detection of a resistant population is suffi-
cient to exclude macrolides from the eradication therapy
to be implemented.
Moreover, for 22 biopsies where A2143G was detected
by DPO-PCR, the corresponding 475 bp amplicon was
alone in only 4 cases which means that for these
corresponding DNAs the reverse H. pylori 23S rDNA
apparently failed to hybridize and to generate the addi-
tional 621 bp amplicon. We believe that this is the
reason why, in some rare cases, false negatives by DPO-
PCR can occur (a total of 3 in the present study). The
primer pairs which allow the amplification of the
H. pylori 23S rDNA could be slightly modified to avoid
this problem.
Conclusion
Users should keep in mind that whenever possible
H. pylori culture should be performed, and only in cases
where standard microbiology fails, the use of molecular
methods are really indicated. The rationale behind this
is that not only clarithromycin resistance is of interest
but also that of other antimicrobials like tetracycline,
quinolones, rifamycins and metronidazole. However, the
Seeplex® ClaR-H. pylori ACE detection kit is an excel-
lent molecular test to detect H. pylori in gastric biopsies
and to study its sensitivity to clarithromycin, especially
in laboratories without expertise in culturing this bacter-
ium and without a real-time PCR apparatus. At a time
when clarithromycin resistance is increasing (prevalence
is >20% in many countries), clinical laboratories could
be enticed by this new PCR format.
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